Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Actas Urol Esp (Engl Ed)
1 Anticancer Agents Med Chem
1 Bioengineered
1 Biomedicines
1 Biomolecules
1 BJU Int
2 BMC Cancer
1 BMC Urol
1 Bull Cancer
1 Burns
1 Cancer Immunol Immunother
1 Cancer Sci
1 Chem Asian J
1 Clin Nucl Med
1 Clin Oncol (R Coll Radiol)
1 Curr Oncol
2 Curr Opin Urol
1 Diagnostics (Basel)
2 Dis Markers
1 Eur J Cancer
1 Eur J Radiol
1 Eur J Surg Oncol
1 Eur Urol Focus
2 Eur Urol Oncol
1 Exp Mol Med
1 Expert Rev Anticancer Ther
3 Front Genet
3 Front Oncol
1 Front Public Health
1 Future Oncol
1 Genes (Basel)
1 Genomics
1 Heliyon
1 Hum Pathol
1 In Vivo
2 Int J Mol Sci
2 Int J Urol
1 iScience
1 J Appl Stat
1 J Biochem Mol Toxicol
1 J Comput Assist Tomogr
1 J Cutan Pathol
1 J Geriatr Oncol
1 J Hazard Mater
1 J Med Case Rep
1 J Urol
1 JCO Precis Oncol
1 Medicine (Baltimore)
2 Metabolites
4 MMW Fortschr Med
1 Mol Biol Rep
1 Mol Cancer Res
1 Mol Med Rep
1 Nat Rev Urol
1 Neoplasia
1 Nephrol Ther
1 Nutr Cancer
1 Onco Targets Ther
1 Oncol Lett
1 Ophthalmic Surg Lasers Imaging Retina
1 Pan Afr Med J
1 PLoS One
2 Sci Rep
2 Transl Cancer Res
1 Urol Ann
1 Urol Oncol
4 Urology
1 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Actas Urol Esp (Engl Ed)

  1. CULPAN M, Kazan O, Acar HC, Iplikci A, et al
    The probability of residual tumor detection in the second transurethral resection of pT1 urothelial bladder cancer according to the risk factors.
    Actas Urol Esp (Engl Ed). 2022 Jun 17. pii: S2173-5786(22)00045.
    PubMed         Abstract available

    Anticancer Agents Med Chem

  2. HAN L, Li P, Fu X, Huang Z, et al
    Aesculetin inhibits proliferation and induces mitochondrial apoptosis in bladder cancer cells by suppressing the MEK/ERK signaling pathway.
    Anticancer Agents Med Chem. 2022 Jun 15. pii: ACAMC-EPUB-124491.
    PubMed         Abstract available


  3. DONG Y, Ding D, Gu J, Chen M, et al
    Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-beta signalling pathway.
    Bioengineered. 2022;13:14282-14298.
    PubMed         Abstract available


  4. CHUGHTAI AA, Pannhausen J, Dinger P, Wirtz J, et al
    Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR.
    Biomedicines. 2022;10.
    PubMed         Abstract available


  5. MORIWAKI M, Le TT, Sung SY, Jotatsu Y, et al
    Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.
    Biomolecules. 2022;12.
    PubMed         Abstract available

    BJU Int

  6. JUBBER I, Mitchell S, Hussain S, Tsoi H, et al
    Social deprivation and bladder cancer: cause or affect for disparities in survival for affected women.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15832.

    BMC Cancer

  7. ZHANG Q, Zhang W, Lin T, Lu W, et al
    Mass cytometry reveals immune atlas of urothelial carcinoma.
    BMC Cancer. 2022;22:677.
    PubMed         Abstract available

  8. JIANG L, Chen S, Pan Q, Zheng J, et al
    The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
    BMC Cancer. 2022;22:676.
    PubMed         Abstract available

    BMC Urol

  9. LU D, Wu Y, Liao S, Xie X, et al
    Delayed ileal neobladder fistula caused by bladder stones: a case report.
    BMC Urol. 2022;22:87.
    PubMed         Abstract available

    Bull Cancer

  10. HOUEDE N, Flahault C, Gross-Goupil M, Le Clanche S, et al
    [Locally advanced or metastatic bladder cancer: Identification of barriers and levers of patients' pathway in France].
    Bull Cancer. 2022 Jun 17. pii: S0007-4551(22)00187.
    PubMed         Abstract available


  11. WANG B, Hu L, Chen Y, Zhu B, et al
    Aspartate transaminase/alanine transaminase (De Ritis ratio) predicts survival in major burn patients.
    Burns. 2022;48:872-879.
    PubMed         Abstract available

    Cancer Immunol Immunother

  12. JI N, Long M, Garcia-Vilanova A, Ault R, et al
    Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.
    Cancer Immunol Immunother. 2022 Jun 24. pii: 10.1007/s00262-022-03236.
    PubMed         Abstract available

    Cancer Sci

  13. MATSUE T, Gi M, Shiota M, Tachibana H, et al
    The carbonic anhydrase inhibitor acetazolamide inhibits urinary bladder cancers via suppression of beta-catenin signaling.
    Cancer Sci. 2022 Jun 20. doi: 10.1111/cas.15467.
    PubMed         Abstract available

    Chem Asian J

  14. HUO F, Zhang Y, Li Y, Bu H, et al
    Mannose-targeting concanavalin A-epirubicin conjugate for targeted intravesical chemotherapy of bladder cancer.
    Chem Asian J. 2022 Jun 17. doi: 10.1002/asia.202200342.
    PubMed         Abstract available

    Clin Nucl Med

  15. RIETBERGEN DDD, van Gennep EJ, KleinJan GH, Donswijk M, et al
    Evaluation of the Hybrid Tracer Indocyanine Green-99mTc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer-A Prospective Pilot Study.
    Clin Nucl Med. 2022 Jun 18. pii: 00003072-990000000-00181.
    PubMed         Abstract available

    Clin Oncol (R Coll Radiol)

  16. NAKATA M, Shimbo T, Kihara A, Sato C, et al
    Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2022 Jun 14. pii: S0936-6555(22)00266.
    PubMed         Abstract available

    Curr Oncol

  17. TOMIYAMA E, Fujita K, Nakano K, Kuwahara K, et al
    Trop-2 in Upper Tract Urothelial Carcinoma.
    Curr Oncol. 2022;29:3911-3921.
    PubMed         Abstract available

    Curr Opin Urol

  18. VARTOLOMEI MD, Ferro M, Roth B, Teoh JY, et al
    Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.
    Curr Opin Urol. 2022 Jun 27. pii: 00042307-990000000-00015.
    PubMed         Abstract available

  19. COMPERAT E, Wasinger G, Oszwald A, Pradere B, et al
    Nonmuscle-invasive bladder cancer, old problems, new insights.
    Curr Opin Urol. 2022;32:352-357.
    PubMed         Abstract available

    Diagnostics (Basel)

  20. BIERI U, Buser L, Wettstein MS, Eberli D, et al
    Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.
    Diagnostics (Basel). 2022;12.
    PubMed         Abstract available

    Dis Markers

  21. YAN Y, Li J, Ye M, Li Z, et al
    Tropomyosin Is Potential Markers for the Diagnosis and Prognosis of Bladder Cancer.
    Dis Markers. 2022;2022:6936262.
    PubMed         Abstract available

  22. XIAYU K, GuoGang C, CanXuan L, WeiBin X, et al
    Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction.
    Dis Markers. 2022;2022:2360299.
    PubMed         Abstract available

    Eur J Cancer

  23. LIU Z, Jin K, Zeng H, Shao F, et al
    B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Eur J Cancer. 2022;171:133-142.
    PubMed         Abstract available

    Eur J Radiol

  24. RIGIROLI F, Zhang D, Molinger J, Wang Y, et al
    Automated versus manual analysis of body composition measures on computed tomography in patients with bladder cancer.
    Eur J Radiol. 2022;154:110413.
    PubMed         Abstract available

    Eur J Surg Oncol

  25. LETICA-KRIEGEL AS, Tin AL, Nash GM, Benfante NE, et al
    Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy.
    Eur J Surg Oncol. 2022;48:1427-1432.
    PubMed         Abstract available

    Eur Urol Focus

  26. NUMAKURA K, Kobayashi M, Ishida T, Okane K, et al
    Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study.
    Eur Urol Focus. 2022 Jun 15. pii: S2405-4569(22)00130.
    PubMed         Abstract available

    Eur Urol Oncol

  27. AFFERI L, Lonati C, Montorsi F, Briganti A, et al
    Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.
    Eur Urol Oncol. 2022 Jun 14. pii: S2588-9311(22)00062.
    PubMed         Abstract available

  28. TAN WS, Steinberg G, Witjes JA, Li R, et al
    Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
    Eur Urol Oncol. 2022 Jun 16. pii: S2588-9311(22)00088.
    PubMed         Abstract available

    Exp Mol Med

  29. HEO J, Lee J, Nam YJ, Kim Y, et al
    The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer.
    Exp Mol Med. 2022 Jun 21. pii: 10.1038/s12276-022-00786.
    PubMed         Abstract available

    Expert Rev Anticancer Ther

  30. BHANVADIA RR, Lotan Y
    Progress in the development of tissue-based biomarkers for urothelial cancer.
    Expert Rev Anticancer Ther. 2022;22:605-619.
    PubMed         Abstract available

    Front Genet

  31. KAVCIC N, Peric I, Zagorac A, Kokalj Vokac N, et al
    Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.
    Front Genet. 2022;13:839598.
    PubMed         Abstract available

  32. ZHANG Y, Hua S, Jiang Q, Xie Z, et al
    Identification of Feature Genes of a Novel Neural Network Model for Bladder Cancer.
    Front Genet. 2022;13:912171.
    PubMed         Abstract available

  33. SUN X, Xu H, Liu G, Chen J, et al
    A Robust Immuno-Prognostic Model of Non-Muscle-Invasive Bladder Cancer Indicates Dynamic Interaction in Tumor Immune Microenvironment Contributes to Cancer Progression.
    Front Genet. 2022;13:833989.
    PubMed         Abstract available

    Front Oncol

  34. WANG S, Xu D, Gao B, Yan S, et al
    Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.
    Front Oncol. 2022;12:915542.
    PubMed         Abstract available

  35. LU Y, Wang S, Wang Y, Li M, et al
    Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy.
    Front Oncol. 2022;12:879828.
    PubMed         Abstract available

  36. QIAN J, Yang L, Hu S, Gu S, et al
    Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images.
    Front Oncol. 2022;12:899897.
    PubMed         Abstract available

    Front Public Health

  37. DING L, Xia B, Zhang Y, Liu Z, et al
    Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.
    Front Public Health. 2022;10:870920.
    PubMed         Abstract available

    Future Oncol

  38. PAL SK, Somford DM, Grivas P, Sridhar SS, et al
    Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
    Future Oncol. 2022;18:2599-2614.
    PubMed         Abstract available

    Genes (Basel)

  39. HU S, Gu S, Wang S, Qi C, et al
    Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.
    Genes (Basel). 2022;13.
    PubMed         Abstract available


  40. QIU T, Chen Y, Meng L, Xu T, et al
    Identification of a metabolism-related gene signature predicting overall survival for bladder cancer.
    Genomics. 2022;114:110402.
    PubMed         Abstract available


  41. LIU Z, Xing L, Zhu Y, Shi P, et al
    Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer.
    Heliyon. 2022;8:e09643.
    PubMed         Abstract available

    Hum Pathol

  42. TAYLOR AS, Acosta AM, Al-Ahmadie HA, Mehra R, et al
    Precursors of Urinary Bladder Cancer: Molecular Alterations and Biomarkers.
    Hum Pathol. 2022 Jun 15. pii: S0046-8177(22)00151.
    PubMed         Abstract available

    In Vivo

  43. NISHIMURA K, Ishihara H, Kondo T, Toguchi M, et al
    Assessment of Feasibility of Robot-assisted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy.
    In Vivo. 2022;36:1801-1806.
    PubMed         Abstract available

    Int J Mol Sci

  44. TOHI Y, Taoka R, Zhang X, Matsuoka Y, et al
    Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  45. MAESAKA F, Kuwada M, Horii S, Kishi S, et al
    Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

    Int J Urol

  46. ARAI T, Sazuka T, Sato H, Imamura Y, et al
    Efficacy of photodynamic diagnosis-assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
    Int J Urol. 2022 Jun 20. doi: 10.1111/iju.14962.

  47. NOHARA T
    Editorial Comment to Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 Jun 19. doi: 10.1111/iju.14967.


  48. BONDARUK J, Jaksik R, Wang Z, Cogdell D, et al
    The origin of bladder cancer from mucosal field effects.
    iScience. 2022;25:104551.
    PubMed         Abstract available

    J Appl Stat

  49. PATHAK A, Kumar M, Singh SK, Singh U, et al
    Bayesian inference: Weibull Poisson model for censored data using the expectation-maximization algorithm and its application to bladder cancer data.
    J Appl Stat. 2020;49:926-948.
    PubMed         Abstract available

    J Biochem Mol Toxicol

  50. QI Y, Toyooka T, Horiguchi H, Koda S, et al
    2-mercaptobenzothiazole generates gamma-H2AX via CYP2E1-dependent production of reactive oxygen species in urothelial cells.
    J Biochem Mol Toxicol. 2022;36:e23043.
    PubMed         Abstract available

    J Comput Assist Tomogr

  51. AWIWI MO, Vikram R
    Radiologic Diagnosis and Staging of Bladder Cancer: An Update.
    J Comput Assist Tomogr. 2022 Jun 18. pii: 00004728-990000000-00056.
    PubMed         Abstract available

    J Cutan Pathol

  52. AL QA'QA' S, Tiwari R, van der Kwast T
    Penile extramammary Paget disease associated with urothelial carcinoma in situ: Case report and literature review.
    J Cutan Pathol. 2022;49:663-668.
    PubMed         Abstract available

    J Geriatr Oncol

  53. ALATI A, Fabiano E, Geiss R, Mareau A, et al
    Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
    J Geriatr Oncol. 2022 Jun 15. pii: S1879-4068(22)00135.
    PubMed         Abstract available

    J Hazard Mater

  54. LIU H, Gu J, Huang Z, Han Z, et al
    Fine particulate matter induces METTL3-mediated m(6)A modification of BIRC5 mRNA in bladder cancer.
    J Hazard Mater. 2022;437:129310.
    PubMed         Abstract available

    J Med Case Rep

  55. SOLEK J, Kalwas M, Sobczak M, Debska-Szmich S, et al
    Urothelial carcinoma of the prostate with raised beta-hCG levels: a case report.
    J Med Case Rep. 2022;16:238.
    PubMed         Abstract available

    J Urol

  56. GESSNER KH, Siemens DR, Bjurlin MA
    Re: Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Jun 21:101097JU0000000000002832. doi: 10.1097/JU.0000000000002832.

    JCO Precis Oncol

  57. ALMASSI N, Whiting K, Toubaji A, Lenis AT, et al
    Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
    JCO Precis Oncol. 2022;6:e2100392.
    PubMed         Abstract available

    Medicine (Baltimore)

  58. SILVA DJ, Mesquita A
    Complete and long-lasting response to immunotherapy: A case report of urothelial cancer.
    Medicine (Baltimore). 2022;101:e28940.
    PubMed         Abstract available


  59. ZHUANG J, Yang X, Zheng Q, Li K, et al
    Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.
    Metabolites. 2022;12.
    PubMed         Abstract available

  60. KAMI REDDY KR, Piyarathna DWB, Kamal AHM, Putluri V, et al
    Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer.
    Metabolites. 2022;12.
    PubMed         Abstract available

    MMW Fortschr Med


    MMW Fortschr Med. 2022;164:65.

  62. EBNER B, Eismann L, Volz Y, Bischoff R, et al
    [Surgical and systemic therapy of bladder cancer].
    MMW Fortschr Med. 2022;164:40-42.

  63. EISMANN L, Ebner B, Volz Y, Bischoff R, et al
    [Initial symptoms and diagnostics of bladder cancer].
    MMW Fortschr Med. 2022;164:36-39.

  64. STIEF CG

    MMW Fortschr Med. 2022;164:5.

    Mol Biol Rep

  65. ALKANLI N, Ay A, Aydin PK, Cevik G, et al
    Investigation of the relationship between MTRR A66G, MTR A2756G gene variations and cell anomalies in early diagnosis and progression of bladder cancer.
    Mol Biol Rep. 2022 Jun 17. pii: 10.1007/s11033-022-07597.
    PubMed         Abstract available

    Mol Cancer Res

  66. IYENGAR PV, Marvin DL, Lama D, Tan TZ, et al
    TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling.
    Mol Cancer Res. 2022 Jun 22. pii: 705055. doi: 10.1158/1541-7786.MCR-20-1029.
    PubMed         Abstract available

    Mol Med Rep

  67. SMITH TAD, Lane B, More E, Valentine H, et al
    Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature.
    Mol Med Rep. 2022;26.
    PubMed         Abstract available

    Nat Rev Urol

  68. STONE L
    Biomarkers for bladder cancer diagnosis, prognosis, monitoring and treatment.
    Nat Rev Urol. 2022 Jun 16. pii: 10.1038/s41585-022-00620.


  69. CONDE M, Frew IJ
    Therapeutic significance of ARID1A mutation in bladder cancer.
    Neoplasia. 2022;31:100814.
    PubMed         Abstract available

    Nephrol Ther

  70. KBIROU A, Hagguir H, Moataz A, Dakir M, et al
    Acute renal failure and bladder tumors, about 106 cases.
    Nephrol Ther. 2022;18:202-206.
    PubMed         Abstract available

    Nutr Cancer

  71. XUE W, Hu X, Zhang Y
    The Association of Controlling Nutritional Status (CONUT) Score with Survival in Patients with Surgically Treated Renal Cell Carcinoma and Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Nutr Cancer. 2022;74:1907-1916.
    PubMed         Abstract available

    Onco Targets Ther

  72. LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis [Retraction].
    Onco Targets Ther. 2022;15:681-682.
    PubMed         Abstract available

    Oncol Lett

  73. CHABAUD S, Pellerin E, Caneparo C, Ringuette-Goulet C, et al
    Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension.
    Oncol Lett. 2022;24:220.
    PubMed         Abstract available

    Ophthalmic Surg Lasers Imaging Retina

  74. KIRYAKOZA LC, Diaz JD, Priluck J, Davis J, et al
    A Case of Bilateral Diffuse Uveal Melanocytic Proliferation in the Setting of Urothelial Carcinoma of the Ureter: A Failed Response to Plasmapheresis.
    Ophthalmic Surg Lasers Imaging Retina. 2022;53:350-353.
    PubMed         Abstract available

    Pan Afr Med J

  75. NASROLLAHI H, Ahmed F, Eslahi A, Pilehroud MG, et al
    Sarcomatoid variant of urothelial carcinoma in the renal pelvis with brain metastasis: a case report.
    Pan Afr Med J. 2022;41:233.
    PubMed         Abstract available

    PLoS One

  76. ABDELGAWAD A, Hashem A, Mosbah A, Eissa LA, et al
    A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
    PLoS One. 2022;17:e0266371.
    PubMed         Abstract available

    Sci Rep

  77. VLAAR JM, Borgman A, Kalkhoven E, Westland D, et al
    Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer.
    Sci Rep. 2022;12:10081.
    PubMed         Abstract available

  78. XUE MQ, Wang YL, Wang JC, Wang XD, et al
    Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer.
    Sci Rep. 2022;12:10082.
    PubMed         Abstract available

    Transl Cancer Res

  79. LI R, Xia Y, Chen X, Li X, et al
    Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.
    Transl Cancer Res. 2022;11:1005-1016.
    PubMed         Abstract available

  80. ZHENG W, Zhao Y, Wang T, Zhao X, et al
    Identification of hub genes associated with bladder cancer using bioinformatic analyses.
    Transl Cancer Res. 2022;11:1330-1343.
    PubMed         Abstract available

    Urol Ann

  81. MEHMOOD S, Alothman KI, Al Rumayyan M, Altaweel WM, et al
    Clinical behavior and survival outcome of urothelial bladder cancer in young adults.
    Urol Ann. 2022;14:162-166.
    PubMed         Abstract available

    Urol Oncol

  82. TONG S, Hu X, Li Y
    Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
    Urol Oncol. 2022 Jun 16. pii: S1078-1439(22)00189.
    PubMed         Abstract available


  83. LABBATE CV, Kuchta K, Park S, Agarwal PK, et al
    Incidence of Preoperative Antibiotic Use and Its Association with Postoperative Infectious Complications after Radical Cystectomy.
    Urology. 2022;164:169-177.
    PubMed         Abstract available

  84. CHEN J, Cai D, Gong K, Zhu S, et al
    Collecting Duct Carcinoma of the Kidney: Analysis of 74 Cases From Multiple Centers.
    Urology. 2022;164:163-168.
    PubMed         Abstract available

  85. ANDERSON AL, Tollefson MK, Frank I, Peffley ND, et al
    Intraoperative Ventilatory Pressures During Robotic Assisted vs Open Radical Cystectomy.
    Urology. 2022;164:157-162.
    PubMed         Abstract available

  86. NODIT PG, Bienvenu JM
    Rhabdomyosarcoma of the Urinary Bladder Occurring in an Adult.
    Urology. 2022;164:306-307.

    World J Urol

  87. CARRASCO R, Ingelmo-Torres M, Gomez A, Roldan FL, et al
    Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer.
    World J Urol. 2022 Jun 17. pii: 10.1007/s00345-022-04061.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.